A growing U.S. demand for faster, AI-powered tools in cardiopulmonary care is opening up substantial commercial opportunities for Australian medtech company 4DMedical (ASX:4DX).

The Melbourne-based imaging innovator has secured a significant contract with Intermountain Health—one of the United States’ largest and most respected health systems—for the rollout of its newly FDA-cleared Pulmonary Hypertension Analysis (PHA™) product.

CEO Highlights Strategic Breakthrough

“We are thrilled to partner with Intermountain Health through our distribution agreement with Nuance,” said 4DMedical MD/CEO and Founder Andreas Fouras. “Intermountain’s leadership in data-driven, high-quality care makes them an ideal partner to lead this important innovation in cardio-pulmonary health care delivery.”

Deploying PHA Across 33 Hospitals 

The agreement will see 4DMedical’s PHA™ solution deployed throughout Intermountain’s 33 hospitals and 400 clinics, which serve communities across five U.S. states. The rollout targets acute care environments, where Pulmonary Embolism Response Teams (PERTs) urgently need tools that provide rapid, automated analysis of right ventricle and pulmonary artery diameters—key signs of pulmonary hypertension following a pulmonary embolism.

The AI-driven algorithm generates results that would otherwise take much longer to process manually, offering clinicians an edge in time-sensitive diagnostic settings.

Gaining Scale Through Nuance and Microsoft

The contract win was achieved through 4DMedical’s distribution partnership with Nuance Communications, a Microsoft-owned leader in AI-powered clinical documentation. Integration into Nuance’s PowerScribe radiology workflow platform means PHA can be adopted at scale with minimal disruption to existing processes.

Long-Term Growth Potential Baked Into Contract Terms

While the first year of payments from Intermountain is fixed at a relatively low scan volume, the agreement is structured to scale up in future years. As use of the PHA™ product expands throughout Intermountain’s network, the revenue opportunity for 4DMedical is expected to grow substantially.

“This contract establishes us within a health system of 33 hospitals and nearly 4,000 physicians,” Fouras said. “As the contract transitions to full commercial terms, this revenue stream will become meaningful for us.”

Positioned for broader U.S. expansion

Intermountain Health is one of just three designated Microsoft Innovation Sites in the U.S., making this partnership a strategic showcase for 4DMedical. The deal represents the first major commercial deployment of the PHA™ product and is seen as a signal of broader U.S. market acceptance.

Strong growth momentum in play

According to the CEO, 4DMedical is already seeing “rapid growth in sites and scans month on month.” This momentum is expected to accelerate further as the company advances other key initiatives, including final preparations for its CT:VQ submission to the U.S. FDA, aimed at market entry later in calendar year 2025.

“We stand at a very exciting moment,” Fouras said. “This growth is soon to be boosted as our investment in the relationship with Philips matures, and preparations for the CT:VQ submission to the FDA for 510(k) clearance nears completion, paving the way for market entry later in CY2025.”

With a growing U.S. footprint, scalable distribution via Microsoft-owned Nuance, and an expanding product suite, 4DMedical is steadily positioning itself as a global leader in AI-powered respiratory diagnostics. The Intermountain Health deal is more than a contract—it’s a foothold in one of the world’s most influential healthcare systems.

For investors, it may represent an early signal that 4DMedical’s commercialisation strategy is beginning to convert breakthrough technology into recurring revenue.